Home › Compare › CSGEF vs ABBV
CSGEF yields 5.62% · ABBV yields 3.06%● Live data
📍 CSGEF pulled ahead of the other in Year 1
Combined, CSGEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSGEF + ABBV for your $10,000?
China Suntien Green Energy Corporation Limited, together with its subsidiaries, develops and utilizes clean energy in Mainland China. It operates through three segments: Natural Gas, Wind Power and Solar Energy, and Other. The Natural Gas segment sells natural gas and gas appliances, as well as provides construction and connection services for natural gas pipelines. The Wind/Solar Power segment engages in the development, management, and operation of the wind farm and solar power plants; and generates and sells electric power for power grid companies. The Other segment engages in the management and property leasing business. As of December 31, 2021, the company owned 7 long-distance natural gas transmission pipelines, 20 high-pressure branch pipelines, 31 urban gas projects, 25 distribution stations, 19 gate stations, 6 compressed natural gas (CNG) primary filling stations, 3 CNG secondary filling stations, 3 liquefied natural gas filling station, and 2 L-CNG joint filling stations. It also had a wind power consolidated installed capacity of 5,673.85 megawatts (MW) and installed capacity under management of 5,869.45 MW, as well as an attributable installed capacity of 5,311.60 MW. It also engages in the provision of project investment, investment management, and technical development services; and investment and sale of solar energy appliances, as well as provides service consultancy services. Further, it offers operation and maintenance of photovoltaic power stations and logistics, loading and unloading, and transportation services. The company was incorporated in 2010 and is headquartered in Shijiazhuang, the People's Republic of China.
Full CSGEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.